Venetoclax to shrink HIV reservoir in people on stable ART
Treatments studied
Part of Infections clinical trials.
This Phase 1/2 study tests whether venetoclax can help reduce the “HIV reservoir,” which is a hidden group of HIV-infected cells, while you stay on your usual HIV treatment. It also looks at whether the drug helps these infected cells die off in a controlled, safe way.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed HIV-1 infection and are between 18 and 65 years old.
- You have been on combination HIV treatment (ART) for at least 2 years and have stayed on the same ART regimen for at least 4 weeks before screening.
- Your viral load on ART is very low: under 20 copies/mL at screening, and under 50 copies/mL for over 2 years (with allowances if levels briefly rose then returned to under 50).
- Your immune system is strong: CD4 count must be over 500 cells/µL at screening, and it has been over 500 at least twice in the past 24 months.
- You must be willing and able to keep taking ART the same way during the study and follow study visits and procedures; you must be able to give informed consent.
- You must be able to manage venetoclax-drug safety rules: no venetoclax-type “pro-apoptosis/BCL-2” drugs for cancer use, no certain strong interacting medicines (especially some anti-fungal/antibiotic/heart/anti-viral and liver-enzyme medicines), and no major liver, kidney, blood count, or serious heart problems. (Your study doctor will review your current meds and recent health.)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares how active the immune system is and how large the “hidden” HIV reservoir is in people on two different HIV treatment types. It may help researchers understand whether staying on a tenofovir-containing regimen leads to better control of HIV hiding in the body.
This study tests whether combining two or more investigational drugs that can activate the hidden HIV reservoir in your body might help eliminate it. The goal is to see if this approach is safe and could help lead to a cure for HIV.
This study looks at where HIV hides in the body (called the viral reservoir) in men whose HIV is well controlled with Biktarvy. Researchers want to see how the levels of HIV medicines in the body relate to these hidden virus cells, which may help improve future treatments.
This study tests whether giving two experimental drugs together can help your immune system find and destroy hidden HIV cells. It aims to see if this approach can reduce the amount of virus in your body even while you're on your regular HIV medications.
This study tests two drugs, baricitinib and sirolimus, alone or together, to see if they can help control HIV after you stop your usual HIV medications for a short time. The goal is to see if these drugs can keep the virus from rebounding.
This trial tests whether adding venetoclax, a drug that helps infected cells die, at the start of HIV treatment can lower the amount of hidden virus that stays in the body. It may help reduce the HIV reservoir.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.